Overview

Obesity is influenced by genetics, environment, and poor lifestyle. The pathogenesis is complex and involves decreased basal metabolic rate (BMR), mitochondrial dysfunction, abnormal glucose uptake in skeletal muscle, age-related changes in the imbalance between protein synthesis and degradation, etc. Exercise is a powerful weight loss tool that leads to weight loss or maintenance of weight. Muscle-associated myokine has been identified as potentially responsible for weight stability and weight loss. They are hormones produced by myocytes in response to increased energy demands during processes such as cell proliferation and differentiation. Myokines act in endocrine ways, paracrine ways, etc., and may play a key role in appetite control, energy balance, weight loss, weight maintenance, and recovery. They may be potential key targets for appetite control, weight regulation, and treatment of obesity. Protheragen provides a myokines-targeting high-quality anti-obesity therapeutic development service based on a deep understanding of obesity mechanisms.

Your Best Partner for Myokines-Targeting Anti-Obesity Therapeutic Development Service

Our team conducts in-depth studies on the role of myokine in driving feeding behavior, energy expenditure, etc., and develops highly effective measures to prevent and treat obesity. We support our clients' anti-obesity research with industry-leading technologies and innovative solutions. Specific services include the following:

Anti-Obesity Drug Development

Computer-Aided Drug Design: We use a variety of advanced computational chemistry tools to complete the design, screening, and optimization of anti-obesity drugs targeting myokine. The entire simulation includes target analysis, high-throughput screening, lead compound discovery, compound optimization, and durability prediction. Our analytical team consists of several computational chemists with extensive pharmaceutical experience. We shorten the anti-obesity drug development cycle and increase the success rate by predicting the binding strength and drug-likeness of compounds to receptors.

Drug Development: Natural products are a treasure trove of anti-obesity agents that exert their anti-obesity effects through different mechanisms. Comprehensive research on natural products has the potential to accelerate the development of obesity treatment strategies with higher efficacy and lower side effects. For example, resveratrol promotes fat browning by modulating several myokine and adipokines, ultimately leading to weight loss, enhanced glucose homeostasis, and improved insulin resistance. We screen various natural products, including phenolic compounds and terpenoids, and evaluate their potential in the treatment of obesity. In addition to this, we also analyze various myokines such as brain-derived neurotrophic factor (BDNF), irisin, etc., on food intake, body weight, and others in obesity models.

Other Therapies Development

Irisin is a pleiotropic myokine that promotes white adipose tissue browning and increases the expression of mitochondrial uncoupling protein 1. Its overexpression is found to promote weight loss and improve glucose metabolism in mice on a high-fat diet and may be a novel target for obesity treatment. We use gene editing and other pathways to enhance irisin expression and evaluate the effectiveness of these strategies in the treatment of obesity. In addition to this, we also analyze the impact of regulating other myokine expressions in the treatment of obesity.

Preclinical Studies

We have extensive hands-on experience and offer a full range of experimental assays to facilitate preclinical studies of anti-obesity therapies. A variety of In Vivo and In Vitro Models have been constructed to analyze obesity pathogenesis, myokine-obesity correlation, anti-obesity drug screening, and therapy evaluation. Based on these rich obesity models, we test the pharmacodynamics, pharmacokinetics, safety assessment, and other bioassays of anti-obesity therapies targeting myokine.

Workflow

Applications

• The study of anti-obesity therapies targeting myokine contributes to a deeper understanding of obesity pathogenesis and the correlation between myokine and obesity.
• Research on anti-obesity therapies targeting myokine provides valuable information for the development of treatments for diabetes and other related complications.
• The development of anti-obesity therapies that target myokine provides valuable information for the development of combination anti-obesity therapies that target multiple targets simultaneously.

Advantages

• We have a wide range of efficient computer analysis tools to provide computational guidance and assistance in anti-obesity drug design.
• We have a rigorous quality management system and state-of-the-art technology to ensure the high quality and efficiency of each anti-obesity development project.
• Our experienced researchers maintain good communication with clients throughout the experiment and answer any questions.

Other Innovative Services

We are at the forefront of obesity research and treatment development and have developed a range of specialty services to support individual research breakthroughs. Comprehensive obesity analytic testing services are provided that examine multifactorial root causes, including genetic, environmental, and metabolic factors. We also provide advanced diagnostic testing services and utilize algorithms and genetic information to predict obesity risk. Our team specializes in mining useful information from biomarkers, microbiome and pathobiology analysis results, and gene editing to correct genetic abnormalities. Professional weight loss and weight management services for scientific monitoring and management are also our feature services.

Publication Data

Frequently Asked Questions

Which myokines are associated with obesity?

• BDNF: It is an important biomolecule for weight regulation and appetite control. In animal models, its knockdown leads to bulimia and obesity. Central administration of BDNF reduces food intake to promote weight loss. Genome-wide association studies have shown that single nucleotide polymorphisms in BDNF are associated with an increased risk of obesity, making BDNF a potential target for obesity treatment research.
• Irisin: It is found that increasing plasma irisin levels result in weight loss and subcutaneous adipose tissue browning in obese mice. Irisin provides a new potential target for the treatment of obesity.
• Muscle growth inhibitor: It is a negative regulator of skeletal muscle mass and is associated with increased muscle mass. Inhibition of muscle growth inhibitors reduces overfeeding in a mouse model of lipodystrophy. It is used as a target for research and to evaluate its effects in preventing weight gain, among other things.
• Other myokine: In addition to this, apelin, β-aminoisobutyric acid, etc., also play the role of myokine in improving metabolism, anti-inflammation, etc. They provide new targets for the treatment of obesity.

What types of services do we provide?

Anti-obesity therapies targeting myokine include therapeutic design, computer simulation, drug screening, and preclinical studies (pharmacodynamics, pharmacokinetics, toxicology, etc.). After understanding our clients' experimental needs, we develop relevant protocols and complete all experiments and analyses.

Protheragen provides a one-stop service for the development of myokine-targeted anti-obesity therapies, from anti-obesity therapy design, and preclinical studies to data analysis. Our strict quality assurance system and standardized operations enable us to provide satisfactory services to our clients. Please feel free to contact us for more details if you are interested in this area or need more information.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Targeting Endocannabinoids for Developing Anti-Obesity Therapeutics
• Targeting Sirtuins for Developing Anti-Obesity Therapeutics